Golden State Equity Partners Grows Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Golden State Equity Partners grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 5.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,930 shares of the company’s stock after buying an additional 950 shares during the quarter. Golden State Equity Partners’ holdings in Mirum Pharmaceuticals were worth $559,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of MIRM. China Universal Asset Management Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 98.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after purchasing an additional 488 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $41,000. Teacher Retirement System of Texas acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $221,000. Arizona State Retirement System acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $222,000. Finally, E Fund Management Co. Ltd. acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at about $223,000.

Mirum Pharmaceuticals Trading Down 0.1 %

Shares of MIRM stock traded down $0.03 during trading hours on Friday, hitting $24.46. 268,335 shares of the company were exchanged, compared to its average volume of 421,713. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $35.56. The company has a current ratio of 4.45, a quick ratio of 4.19 and a debt-to-equity ratio of 1.23. The firm has a fifty day moving average of $26.42 and a 200 day moving average of $28.30.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The company had revenue of $69.55 million for the quarter, compared to analysts’ expectations of $66.73 million. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt purchased 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were purchased at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $347,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Eric Bjerkholt acquired 2,000 shares of the stock in a transaction on Wednesday, March 27th. The stock was bought at an average price of $24.80 per share, with a total value of $49,600.00. Following the completion of the transaction, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Radovich sold 4,303 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. 24.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on MIRM shares. SVB Leerink lowered their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. JMP Securities raised their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, March 14th. Stifel Nicolaus initiated coverage on shares of Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They set a “buy” rating and a $48.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $51.70.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.